Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | DTYMK | P23919 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8136865 | 1.00 | TSHR (0.58) | TSHRL3MBTL1TDP1CES2CES1 | |
| SCHEMBL395696 | 0.90 | TSHR (0.56) | TSHRL3MBTL1TDP1CES2CES1 | |
| SCHEMBL272650 | 0.90 | TSHR (0.61) | TSHRL3MBTL1TDP1CES2CES1 | |
| SCHEMBL4180430 | 0.90 | TSHR (0.61) | TSHRL3MBTL1TDP1CES2CES1 | |
| Hydrochloric Acid SCHEMBL11774750 | 0.89 | TSHR (0.59) | TSHRL3MBTL1TDP1CES2CES1 | |
| SCHEMBL27603247 | 0.88 | PDGFRB (0.55) | TSHRL3MBTL1TDP1CES2CES1 | |
| SCHEMBL8526398 | 0.87 | TSHR (0.53) | TSHRL3MBTL1TDP1CES2CES1 | |
| SCHEMBL3224523 | 0.87 | TSHR (0.53) | TSHRL3MBTL1TDP1CES2CES1 | |
| SCHEMBL26841751 | 0.86 | TSHR (0.56) | TSHRL3MBTL1TDP1CES2CES1 | |
| SCHEMBL31558212 | 0.85 | TSHR (0.51) | TSHRL3MBTL1TDP1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739668-A1 | 1,3-ISOINDOLINEDIONE DERIVATIVES AND HETEROAROMATIC ANALOGUES FOR STIMULATING ENDOTHELIAL CELL-PERICYTE INTERACTION | Academisch Ziekenhuis Leiden (h.o.d.n. LUMC) (NL) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025014359-A1 | 1,3-ISOINDOLINEDIONE DERIVATIVES AND HETEROAROMATIC ANALOGUES FOR STIMULATING ENDOTHELIAL CELL-PERICYTE INTERACTION | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2025-01-16 | — | — | WO | disclosed |
| CN-110891951-B | Compounds of formula (I) | 谢菲尔德大学 | 2024-08-20 | — | — | CN | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| CN-114007695-A | As AM2Heterocyclic spiro-compounds as receptor inhibitors | 谢菲尔德大学 | 2022-02-01 | — | — | CN | disclosed |
| EP-3880308-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | The University Of Sheffield (GB) | 2021-09-22 | — | — | EP | disclosed |
| US-20210113534-A1 | COMPOUNDS | THE UNIVERSITY OF SHEFFIELD (GB) | 2021-04-22 | — | — | US | disclosed |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | YOAKIM CHRISTIANE | 2010-02-18 | — | — | US | disclosed |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | YOAKIM CHRISTIANE | 2010-02-18 | — | — | US | disclosed |
| US-7528167-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-05-05 | — | — | US | disclosed |
| US-7528167-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-05-05 | — | — | US | disclosed |
| EP-1345943-B1 | INHIBITORS OF PAPILLOMA VIRUS | BOEHRINGER INGELHEIM CA LTD (CA) | 2007-03-21 | — | — | EP | disclosed |
| EP-0720601-B1 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2000-10-25 | — | — | EP | disclosed |
| US-5919829-A | Gastrin and cck receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| US-5795907-A | Gastin and CCK receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-08-18 | — | — | US | disclosed |
| EP-0720601-A1 | GASTRIN AND CCK RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995004720-A2 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210113534-A1 | COMPOUNDS | MRGPRX2, MC2R, ADM2 | TSHR 304/4885L3MBTL1 3736/4885TDP1 3875/4885 |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | REV1, CDKN1A, RB1 | TSHR 3563/4885L3MBTL1 1386/4885TDP1 1049/4885 |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | TSHR 171/4885L3MBTL1 4723/4885TDP1 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.